This is a randomised, double-blind, placebo-controlled phase II clinical trial with a
cross-over design to investigate the efficacy of bumetanide in patients with hypokalemic
periodic paralysis (HypoPP).
The aim is to assess the efficacy of bumetanide in reducing severity and duration of a focal
attack of weakness in a hand muscle.
Twelve participants will be recruited.